Drug Trial Radar · NCT05905484
Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Apr 25, 2023
Primary completion
May 31, 2023
Study completion May 31, 2023
Sponsor
- Lead sponsor
- Atea Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will assess the effects of Bemnifosbuvir on cardiac repolarization in healthy Adult Subjects
Conditions
- Healthy Volunteer Study
Interventions
Bemnifosbuvir (BEM)Drug
A single dose of BEM will be administered.
PlaceboDrug
A single dose of matching placebo will be administered.
MoxifloxacinDrug
A single dose of Moxifloxacin will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Placebo-corrected (Δ) change-from-baseline QTc (ΔΔQTc).Time frame: 24 hours prior to dosing thru 48 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Atea Study Site
Québec, Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.